Los Angeles Business Journal

MannKind Shares Surge on Afrezza News

Wednesday, April 2, 2014

MannKind Corp.'s share price more than doubled this morning, a day after its inhaled diabetes treatment was backed by an FDA advisory panel, Bloomberg BusinessWeek reports. Shares at midday fell back slightly to $7.10, a 77 percent gain.